Pascal Biosciences (PAS) Stock Price, News & Analysis

Company Overview

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: C$0.02 to C$0.02
• 50-Day Range: C$0.02 to C$0.02
• 52-Week Range: C$0.02 to C$0.10
• Volume: 4,000 shs
• Average Volume: 52,289 shs
• Market Capitalization: C$983.85 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PAS Stock Analysis - Frequently Asked Questions

How have PAS shares performed this year?

Pascal Biosciences' stock was trading at C$0.02 on January 1st, 2025. Since then, PAS stock has increased by 0.0% and is now trading at C$0.02.
View the best growth stocks for 2025 here.

How do I buy shares of Pascal Biosciences?

Shares of PAS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Pascal Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pascal Biosciences investors own include Aurora Cannabis (ACB), Canadian Natural Resources (CNQ), Corus Entertainment (CJR), Cannabis Wheaton Income (CBWTF), Grande West Transportation Group (BUS), Bausch Health Cos (BHC) and Abattis Bioceuticals (ATT).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:PAS
• CIK: N/A
• Web: www.biommune.net
• Phone: +1-604-6886775
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -340.40%

Debt

• Debt-to-Equity Ratio: 882.79
• Current Ratio: 0.03
• Quick Ratio: 0.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 55.00
• Book Value: C($0.02) per share
• Price / Book: -0.75

Miscellaneous

• Outstanding Shares: 65,590,000
• Free Float: N/A
• Market Cap: C$983.85 thousand
• Optionable: Not Optionable
• Beta: 1.51